Ramelteon
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 319610

CAS#: 196597-26-9

Description: Ramelteon is the first in a new class of sleep agents that selectively binds to the MT1 and MT2 receptors in the suprachiasmatic nucleus (SCN), instead of binding to GABAA receptors, such as with drugs like zolpidem. Ramelteon is approved by the U.S. Food and Drug Administration (FDA) for long-term use. Ramelteon does not show any appreciable binding to GABAA receptors, which are associated with anxiolytic, myorelaxant, and amnesic effects. Ramelteon is a melatonin receptor agonist with both high affinity for melatonin MT1 and MT2 receptors and selectivity over the MT3 receptor.


Price and Availability

Size
Price

50mg
USD 450
500mg
USD 1350
Size
Price

100mg
USD 650
1g
USD 2250
Size
Price

200mg
USD 850

Ramelteon, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide). Shipping fee: from $30.00 (USA); from $45.00 (Canada); from $70.00 (international).


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 319610
Name: Ramelteon
CAS#: 196597-26-9
Chemical Formula: C16H21NO2
Exact Mass: 259.1572
Molecular Weight: 259.349
Elemental Analysis: C, 74.10; H, 8.16; N, 5.40; O, 12.34


Synonym: TAK-375; TAK 375; TAK375; Ramelteon. Brand name: Rozerem.

IUPAC/Chemical Name: (S)-N-(2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl)propionamide

SMILES Code: CCC(=O)NCC[C@@H]1CCC2=C1C3=C(C=C2)OCC3


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Kuriyama A, Honda M, Hayashino Y. Ramelteon for the treatment of insomnia in adults: a systematic review and meta-analysis. Sleep Med. 2014 Apr;15(4):385-92. doi: 10.1016/j.sleep.2013.11.788. Epub 2014 Feb 8. Review. PubMed PMID: 24656909.

2: Shimizu N. [The onset mechanism of nocturia in the elderly and the possibility of ramelteon]. Nihon Rinsho. 2013 Jun;71(6):1116-20. Review. Japanese. PubMed PMID: 23855223.

3: Hiromasa S. [A new strategy of treatment of insomnia in the field of cardiology--potential of ramelteon]. Nihon Rinsho. 2013 Jan;71(1):181-7. Review. Japanese. PubMed PMID: 23631192.

4: Liu J, Wang LN. Ramelteon in the treatment of chronic insomnia: systematic review and meta-analysis. Int J Clin Pract. 2012 Sep;66(9):867-73. doi: 10.1111/j.1742-1241.2012.02987.x. Review. PubMed PMID: 22897464.

5: Mishima K. [New hypnotics ramelteon for the treatment of insomniacs with circadian rhythm disturbance]. Nihon Rinsho. 2012 Jun;70(6):1069-78. Review. Japanese. PubMed PMID: 22690618.

6: Hirai K, Kato K, Nishikawa H, Yukuhiro N, Nishiyama K, Miyamoto M. [Preclinical pharmacological profiles and clinical outcome of the novel melatonin-receptor agonist ramelteon (Rozerem 8 mg).]. Nihon Yakurigaku Zasshi. 2010 Jul;136(1):51-60. Review. Japanese. PubMed PMID: 20628215.

7: Joya FL, Kripke DF, Loving RT, Dawson A, Kline LE. Meta-analyses of hypnotics and infections: eszopiclone, ramelteon, zaleplon, and zolpidem. J Clin Sleep Med. 2009 Aug 15;5(4):377-83. Review. PubMed PMID: 19968019; PubMed Central PMCID: PMC2725260.

8: Miyamoto M. [A novel therapeutic drug: ramelteon]. Nihon Rinsho. 2009 Aug;67(8):1595-600. Review. Japanese. PubMed PMID: 19768947.

9: Pandi-Perumal SR, Srinivasan V, Spence DW, Moscovitch A, Hardeland R, Brown GM, Cardinali DP. Ramelteon: a review of its therapeutic potential in sleep disorders. Adv Ther. 2009 Jun;26(6):613-26. doi: 10.1007/s12325-009-0041-6. Epub 2009 Jun 30. Review. PubMed PMID: 19568703.

10: Miyamoto M. Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. CNS Neurosci Ther. 2009 Winter;15(1):32-51. doi: 10.1111/j.1755-5949.2008.00066.x. Review. PubMed PMID: 19228178; PubMed Central PMCID: PMC2871175.

11: Simpson D, Curran MP. Ramelteon: a review of its use in insomnia. Drugs. 2008;68(13):1901-19. Review. PubMed PMID: 18729542.

12: Reynoldson JN, Elliott E Sr, Nelson LA. Ramelteon: a novel approach in the treatment of insomnia. Ann Pharmacother. 2008 Sep;42(9):1262-71. doi: 10.1345/aph.1K676. Epub 2008 Jul 23. Review. PubMed PMID: 18648020.

13: Sateia MJ, Kirby-Long P, Taylor JL. Efficacy and clinical safety of ramelteon: an evidence-based review. Sleep Med Rev. 2008 Aug;12(4):319-32. doi: 10.1016/j.smrv.2007.12.005. Review. PubMed PMID: 18603221.

14: Miyamoto M. [Drugs for insomnia and improving quality of life (QOL): research and development of ramelteon, an MT1/MT2-receptor agonist]. Nihon Yakurigaku Zasshi. 2008 Jan;131(1):16-21. Review. Japanese. PubMed PMID: 18187878.

15: Pandi-Perumal SR, Srinivasan V, Poeggeler B, Hardeland R, Cardinali DP. Drug Insight: the use of melatonergic agonists for the treatment of insomnia-focus on ramelteon. Nat Clin Pract Neurol. 2007 Apr;3(4):221-8. Review. PubMed PMID: 17410109.

16: Borja NL, Daniel KL. Ramelteon for the treatment of insomnia. Clin Ther. 2006 Oct;28(10):1540-55. Review. PubMed PMID: 17157111.

17: Bellon A. Searching for new options for treating insomnia: are melatonin and ramelteon beneficial? J Psychiatr Pract. 2006 Jul;12(4):229-43. Review. PubMed PMID: 16883148.

18: Wurtman R. Ramelteon: a novel treatment for the treatment of insomnia. Expert Rev Neurother. 2006 Jul;6(7):957-64. Review. PubMed PMID: 16831111.

19: Owen RT. Ramelteon: profile of a new sleep-promoting medication. Drugs Today (Barc). 2006 Apr;42(4):255-63. Review. PubMed PMID: 16703122.

20: Laustsen G, Andersen M. Ramelteon (rozerem) a novel approach for insomnia treatment. Nurse Pract. 2006 Apr;31(4):52-5. Review. PubMed PMID: 16607213.